Page last updated: 2024-12-10
5-azido-udp-glucuronic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
5-azido-UDP-glucuronic acid: used as photoaffinity probe for UDP-glucuronic acid-utilizing proteins; RN given is for beta-32P labelled cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 3081279 |
MeSH ID | M0195109 |
Synonyms (5)
Synonym |
---|
alpha-d-glucopyranuronic acid, 1-p-ester with 5-azidouridine 5'-(trihydrogen diphosphate-p'-32p) |
137528-00-8 |
5-azido-udp-glucuronic acid |
alpha-d-glucopyranuronic acid, 1-p-ester with 5-azidouridine 5'-(trihydrogendiphosphate-p'-32p) |
(2s,3s,4s,5r,6r)-6-[[[(2r,3s,4r,5r)-5-(5-azido-2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxy(32p)phosphoryl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (10)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 10 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.05
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.05) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (10.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (90.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |